Development of an injectable sustained-release formulation of morphine: antinociceptive properties in rats

1998 ◽  
Vol 32 (3) ◽  
pp. 270-275 ◽  
Author(s):  
R. A. R. Tasker ◽  
B. J. Connell ◽  
S. J. Ross ◽  
C. M. Elson

The antinociceptive actions of morphine incorporated into an injectable chitosan-based gel were investigated in rats. Subcutaneous administration of 4.8 mg/kg morphine sulphate in a gel composed of N,O-carboxymethylchitosan (NOCC) and chitosan resulted in significant antinociception within 10 min that was maximal at 60 min and persisted for 6 h. In contrast, the same dose of morphine sulphate injected in sterile saline produced maximal responses at 30 min but only persisted for 2 h. NOCC/chitosan gel was easily injectable using a 22 guage needle and appears stable in long-term storage. No local or systemic adverse effects other than morphine-induced sedation were observed either at the time of injection or during the subsequent 48 h. We conclude that gels composed of chitosan and chitosan derivatives are effective matrices for sustained-release formulations of opioid analgesics capable of providing long-lasting antinociception.

2017 ◽  
Vol 31 (3) ◽  
pp. 219-224 ◽  
Author(s):  
David Sanchez-Migallon Guzman ◽  
Michael H. Court ◽  
Zhaohui Zhu, ◽  
Noémie Summa ◽  
Joanne R. Paul-Murphy

2014 ◽  
Vol 34 (2) ◽  
pp. 205-223 ◽  
Author(s):  
J Zhang ◽  
L Ye ◽  
W Wang ◽  
G Du ◽  
X Yu ◽  
...  

Long-acting injectable formulations of antipsychotics have been an important treatment option to increase the compliance of the patient with schizophrenia by monitoring drug administration and identifying medication noncompliance and to improve the long-term management of schizophrenia. Risperidone, a serotoninergic 5-HT2and dopaminergic D2receptor antagonist, was developed to be a long-acting sustained-release formulation for the treatment of schizophrenia. In this study, 12-week subchronic toxicity study of risperidone-loaded microspheres (RMs) in rats by intramuscular injection with an 8-week recovery phase was carried out to investigate the potential subchronic toxicity of a novel long-acting sustained-release formulation. The results indicated that the dosage of 10–90 mg/kg of RM for 2 weeks did not cause treatment-related mortality. The main drug-related findings were contributed to the dopamine D2receptor and α1-adrenoceptor antagonism of risperidone such as elevation of serum and pituitary prolactin levels and ptosis and changes in reproductive system (uterus, ovary, vagina, mammary gland, testis, seminal vesicle, epididymis, and prostate). In addition, foreign body granuloma in muscle at injection sites caused by poly-lactide-co-glycolide was observed. At the end of the recovery phase, these changes mostly returned to normal. The results indicated that RM had a good safety profile in rats.


Sign in / Sign up

Export Citation Format

Share Document